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OLIGOMERIC ALPHA SYNUCLEIN: 
A HALLMARK IN PARKINSON’S DISEASE DIAGNOSIS
Andrea Macián Nicolás – Genetics degree – Faculty of Biosciences - June 2021
• 10 million people are estimated to have PD
• The risk of developing PD increases with age
• The global prevalence is expected to double by 2030
Clinical diagnosis relies on symptoms 
and detection of neurodegenerative 
damage through imaging techniques
(MRI, PET, SPECT, TCS…)
ANTIBODIES
Treatment includes:
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
There is no cure for Parkinson’s disease
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Quantification of o-α-syn is a more reliable indicator of the disease along with
differentiation between soluble and oligomeric form in biological fluids
FUTURE PERSPECTIVES CONCLUSIONS
SOCIAL AND ECONOMIC IMPACT
• The annual European cost for PD was estimated to
be 13,9 billion euros (2011)
• Burden of the disease: dependency of patients in
factors such as social, economic and family support
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Figure 1. Increase in PD prevalence with age. ▲
Figure 3. Interesting biofluids from most (left) to least (right) promissing. ▲
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Figure 4. Real time quaking induced converision (RT-QuIC).2 ▲ Figure 5. Protein misfolding cyclic amplification (PMCA).3 ▲
Figure 8. Immunoassay technologies, from left to right, Sandwich ELISA, WB and LUMINEX.4 ▲
• Current diagnostic method relies on symptoms and 
imaging techniques à incorrect diagnosis
• There is still a lack of reliable diagnostic method for 
PD
• An important goal is the detection of the early 
stages of the disease à New approaches of 
oligomeric alpha synuclein detection (quantification 
of o-α-syn and o-α-syn/ t-α-syn ratio)
• High sensitivity 
and specificity
• Applicable to 
many biofluids
• Dependent on 
highly trained 
professionals
• Further 
standardization
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Figure 2. Summary of PD biomarkers and their strong or weak points. ▲
Figure 7. Summary of antibodies designed against different conformations of alpha synuclein. ▲
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